Moderna has multiple products at Phase 2 and Phase 3 clinical studies.
In September of 2023, Moderna announced a strategic plan with expectations to launch up to 15 new products across cancer as well as rare and infectious diseases over the next 5 years. (Moderna Scales Back COVID Vaccine Production, Pursues mRNA Medicines Plan, Biospace.com, Sep 13, 2023)
Moderna's product development progress can be summarized as below:
- Multiple programs in development: Moderna boasts a diverse pipeline with multiple programs in various stages of development, encompassing both infectious disease vaccines and mRNA therapeutics across seven different modalities.
- RSV vaccine expected in near future: Their respiratory syncytial virus (RSV) vaccine is nearing the finish line, with potential approval and launch in near future, marking a significant milestone.
- Focus on multiple product launches: The company is shifting its focus to launching multiple products per year from 2025 onwards, indicating confidence in their pipeline and a potential shift towards sustained growth.
- Leading mRNA platform: Moderna's mRNA platform remains at the forefront of the field, offering potential for rapid development and adaptation to address diverse medical needs.
- Details of Moderna's mRNA pipeline: https://www.modernatx.com/en-US/research/product-pipeline
Overall:
Moderna's product development progress remains promising, with the RSV vaccine launch approaching and a focus on driving future product launches. However, managing the decline in COVID-19 vaccine revenue and ensuring the success of other pipeline programs will be crucial for long-term growth. Below is a summary of Moderna's mRNA pipeline - progress. The information here is for reference only, it may also carry mistakes, please check with the reference for details and accuracy. https://www.modernatx.com/research/product-pipeline
Resources:
- Moderna's website: https://www.modernatx.com/
- Moderna's Investors page: https://investors.modernatx.com/overview/default.aspx
- News articles about Moderna's pipeline: